European specialty pharmaceutical company Norgine has announced a £23 million investment to expand medicines manufacturing at its facility in Hengoed, Wales, bringing the company’s total investment in the site to more than £50 million since 2022.
The expansion aims to strengthen pharmaceutical production capacity, support regional economic growth and help ensure a more resilient supply of essential medicines across the UK and Europe.
The new funding will be used to expand production and warehousing capacity at the Hengoed facility, enabling Norgine to meet growing demand for key medicines and enhance the reliability of supply chains. The site is a major hub for the company’s pharmaceutical manufacturing operations and plays a critical role in delivering treatments to patients across multiple markets.
As part of the expansion, the company plans to introduce advanced, high-speed manufacturing technologies and more energy-efficient processes, improving both production efficiency and quality control capabilities. The upgrades are intended to support the long-term sustainability of Norgine’s manufacturing network while strengthening supply resilience for healthcare systems across Europe.
The investment is expected to create more than 40 new skilled jobs in Wales’ growing life sciences sector.
The project has also been supported by the UK government’s Life Sciences Innovative Manufacturing Fund (LSIMF), a program designed to boost domestic manufacturing capacity and strengthen the UK’s health and life sciences industries.
Government officials highlighted the expansion as an example of continued investment in Wales’ life sciences ecosystem.
Secretary of State for Wales, Jo Stevens, said: “We have a thriving life sciences sector in Wales, and this investment from Norgine is a vote of confidence in our Welsh workforce. I am delighted that UK Government funding is supporting the business to continue to grow and create new well-paid jobs. Norgine is a brilliant example of an international business that is flourishing in Wales.”
The announcement was made during a visit to the Hengoed facility by the UK Secretary of State for Wales, underscoring the government’s broader strategy to promote the region as a global destination for high-value manufacturing.
Related: Pharmaville: Powering Life Science Location Decisions
For Norgine, the investment forms part of a broader strategy to modernize and localize pharmaceutical manufacturing across Europe. By expanding capacity and adopting more advanced production technologies, the company aims to ensure patients have reliable access to essential medicines while responding to increasing global demand.
“At Norgine, we believe every scientific breakthrough should be able to reach the patients who need it, and innovative approaches to manufacturing and supply are a vital part of making that possible. By expanding and further enhancing our Hengoed facilities, we are increasing capacity, strengthening quality capabilities and investing in more energy‑efficient production,” said Norgine’s Chief Operating Officer Saulo Martiniano.
“We are proud of this investment, which will help bolster the resilience of UK and European health systems. With the enhanced capabilities at Hengoed, Wales, alongside our site in Dreux, France, and our broad network of manufacturing partners across Europe, we are well placed to navigate uncertainty and deliver medicines efficiently and consistently for years to come.”
The recent £23 million expansion is part of a long-term commitment to Hengoed, Norgine said. The company has invested more than £50 million at the site since 2022 to bolster operations by expanding capacity and forging international manufacturing partnerships with countries like Japan.
The company said it is planning additional investments over the coming years to help build a more resilient supply chain. This will lead to more than 75 new permanent manufacturing, quality and warehouse roles in Wales.
Norgine is a European specialty pharmaceutical company that develops, manufactures and commercializes medicines, primarily in gastroenterology, hepatology and supportive care.
On the development and commercialization front, in December 2025, Norgine signed a licensing agreement worth up to €550 million with Vir Biotechnology to commercialize Vir’s investigational chronic hepatitis D combination therapy (tobevibart and elebsiran) across Europe, Australia and New Zealand. The deal includes a €55 million upfront payment plus up to €495 million in milestone payments and royalties, while Vir retains commercialization rights in the US and other markets.
Pharmaville.com is a smart locator for life science companies to explore global destinations for R&D, clinical trials and manufacturing. Join the waitlist to feature your region or explore locations as you reevaluate your global footprint.
Join or login to leave a comment
JOIN LOGIN